4-Isopropylbenzo[d]thiazol-2-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: 4-Isopropylbenzo[d]thiazol-2-amine
• 英文别名: 4-propan-2-yl-1,3-benzothiazol-2-amine
• 化学式: C₁₀H₁₂N₂S
• mdl: MFCD04971838
• 分子量: 192.28
• InChiKey: GRUGSZVVRNGXOX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  67.2
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Six membered heteroaromatic inhibitors targeting resistant kinase mutations
  申请人：Noronha Glenn

  公开号：US20070149508A1

  公开（公告）日：2007-06-28

  A compound is provided, having the general structure (A): wherein A is an (un)substituted aryl or (un)substituted heteroaryl moiety, G is N, CH, or CR, R is an unsubstituted or substituted lower alkyl, Y is a hydrophobic linking moiety, and L is a substitutent as defined. The compound (A) can be used for treatment of various angiogenic and hematological-associated disorders, such as myeloproliferative disorder in patients who do not respond to kinase-inhibition therapy that comprises administering approved medications.

  提供了一种化合物，其一般结构为(A)：其中A是(未)取代芳基或(未)取代杂环芳基基团，G是N、CH或CR，R是未取代或取代的较低烷基，Y是疏水连接基团，L是定义的取代基。化合物(A)可用于治疗各种与血管生成和血液学有关的疾病，例如在不对包括给予批准药物的激酶抑制治疗做出反应的患者中的骨髓增生性疾病。
• Thiazole inhibitors targeting resistant kinase mutations
  申请人：Noronha Glenn

  公开号：US20070161645A1

  公开（公告）日：2007-07-12

  A compound is provided, having the general structure (A): wherein A is an aryl or heteroaryl group, Y is a hydrophbic linking moiety, and L is a substitutent. The compound (A) can be used for treatment of various angiogenic-associated or hematologic disorders, such as myeloproliferative disorders in patients who do not respond to kinase-inhibition therapy that comprises administering currently used medications.

  提供了一种化合物，具有一般结构（A）：其中A是芳基或杂环芳基基团，Y是疏水连接基团，L是取代基。化合物（A）可用于治疗各种血管生成相关或血液学疾病，例如对于不对目前使用的药物进行激酶抑制治疗反应的患者的骨髓增生性疾病。
• [EN] HETEROCYCLIC COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET LEURS UTILISATIONS
  申请人：KUMQUAT BIOSCIENCES INC

  公开号：WO2022047260A1

  公开（公告）日：2022-03-03

  The present disclosure provides compounds and pharmaceutically acceptable salt thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, the subject compositions and methods are useful for reducing signaling output of oncogenic proteins.

  本公开提供化合物及其药学上可接受的盐，以及使用它们的方法。这些化合物和方法具有多种用途，可以作为治疗剂、诊断工具和研究工具。特别地，这些组合物和方法对于减少致癌蛋白的信号输出是有用的。
• Metallo-β-lactamase inhibitors
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10227331B2

  公开（公告）日：2019-03-12

  The present invention relates to metallo-β-lactamase inhibitor compounds of Formula I: (I) and pharmaceutically acceptable salts thereof, wherein Z, RA, X1, X2 and RB are as defined herein. The present invention also relates to compositions which comprise a metallo-β-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more β-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance.

  本发明涉及式 I 的金属-β-内酰胺酶抑制剂化合物： (I) 及其药学上可接受的盐，其中 Z、RA、X1、X2 和 RB 如本文所定义。本发明还涉及组合物，该组合物包含本发明的金属-β-内酰胺酶抑制剂化合物或其药学上可接受的盐，以及药学上可接受的载体，可选择与β-内酰胺抗生素和/或β-内酰胺酶抑制剂结合使用。本发明进一步涉及治疗细菌感染的方法，包括向患者施用治疗有效量的本发明化合物，与治疗有效量的一种或多种β-内酰胺类抗生素联合使用，也可选择与一种或多种β-内酰胺酶抑制剂化合物联合使用。本发明的化合物在本文所述的克服抗生素耐药性的方法中是有用的。
• [EN] BENZOTHIAZOLYL BIARYL COMPOUND, AND PREPARATION METHOD AND USE<br/>[FR] COMPOSÉ DE BENZOTHIAZOLYLE BIARYLE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION<br/>[ZH] 一类苯并噻唑基联芳基类化合物、制备方法和用途
  申请人：SHANGHAI RINGENE BIOPHARMA CO LTD

  公开号：WO2021218110A1

  公开（公告）日：2021-11-04

  一种如通式I所示的苯并噻唑基联芳基类化合物、或其药学上可接受的盐、或其对映异构体、非对映异构体、互变异构体、扭转异构体、溶剂化物、多晶型物或前药、其制备方法及作为KRAS G12C抑制剂的的应用。